Protocol for a systematic review of psychological treatment for methamphetamine use: an analysis of methamphetamine use and mental health symptom outcomes
Open accessThe DOI matches its Crossref record; 50 of the 55 references it cites were found in a registry or an index; 6 of the 54 sources its claims cite were checked for support.
Abstract
Introduction People who use methamphetamine (MA) regularly, often experience symptoms of mental ill health associated with the use of the drug. These include symptoms of psychosis, depression, anxiety and also cognitive deficits. Accordingly, psychological treatments aim to reduce MA use and related problems, including symptoms of mental ill health. Although there has been a substantial body of research reporting on the evidence of effectiveness of psychological treatments for MA use, there is a paucity of research addressing the effectiveness of these treatments for coexisting symptoms of mental ill health. We aim to address this gap by providing a comprehensive overview of the evidence for psychological treatments for MA use and associated symptoms of mental ill health in experimental/controlled clinical studies. In addition, a critical evaluation of study methods and the outcomes of psychological interventions on MA use and symptoms of mental ill health will be conducted. Methods and analysis The Cochrane Handbook for Systematic Reviews of Interventions and the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement will be used to inform the methods of this review. Eight electronic peer-reviewed databases will be searched. Pilot searches have been conducted for MA literature considering controlled clinical trials only. Eligible articles will be independently assessed against inclusion criteria. Before final analyses are completed, searches will be rerun and if eligible, additional studies will be retrieved for inclusion. A quantitative synthesis of the findings will be reported where possible, and 'summary of findings' tables will be generated for each comparison. Risk ratios and 95% CI (dichotomous outcomes) will be calculated and/or effect size according to Cohen's formula (continuous outcomes) for the primary outcome of each trial. Ethics and dissemination No ethical issues are foreseen. Findings will be disseminated widely to clinicians and researchers via journal publication and conference presentation(s). Trial registration number CRD42016043657. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Overview
CoChat Summary
## TL;DR
This is a protocol for a systematic review, not the review’s results, so it outlines how the authors will assess psychological treatments for methamphetamine (MA) use and co-occurring mental health outcomes. The planned review will synthesize controlled clinical studies in adults using MA and examine MA use, abstinence, and mental health symptoms or disorders.
## Key findings
- Not stated in the paper.
- The authors state this will be “the first systematic review of interventions for methamphetamine (MA) use and associated mental health outcomes.”
- The review will include controlled trials where studies report both MA use and mental health symptoms/disorders at baseline and post-treatment.
- The protocol specifies planned effect measures: risk ratios with 95% CIs for dichotomous outcomes and Cohen’s d for continuous outcomes; if sample sizes are small, Hedge’s g will be used instead.
## Methods
- Systematic review protocol informed by the Cochrane Handbook for Systematic Reviews of Interventions and PRISMA guidelines.
- Planned search of eight electronic databases plus registration databases; eligible studies are controlled clinical trials, including RCTs (cluster and parallel design), with adults over 18 using MA alone or with other substances.
- Planned synthesis includes meta-analysis “if possible,” otherwise narrative synthesis; study quality will be assessed with the Cochrane Risk of Bias tool and overall certainty with GRADE.
## Limitations
- The paper itself notes that most trials have been conducted in Western countries, so generalisability to other contexts is unknown.
- The authors note that if a meta-analysis is appropriate, it assumes interventions are methodologically consistent across studies.
- Evident from the text: this is a protocol, so it reports intended methods rather than actual review findings or effect estimates.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 37 Not checked · 16 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a review conducted by Elkashef et al,25 pharmacotherapies such as bupropion and sertraline did not increase abstinence from MA in groups who received this drug compared with controls.26”
§ Protocol for a systematic review of psychological treatment for methamphetamine use: an analysis of methamphetamine use and mental health symptom outcomes > Introduction > Rationale
What the sources say
- Not checked — no full text of the sourcecites [25] matched to “Bupropion for the treatment of methamphetamine dependence” (2008) source
- Partly supportedcites [26] Anderson, 2015, Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial, Drug Alcohol Depend sourceExperimental — accuracy not yet measured
The Abstract Results and Discussion report that bupropion did not significantly increase methamphetamine abstinence compared with placebo in this trial of less-than-daily users. The paper is a bupropion trial, not a review by Elkashef et al., and the searched passages do not support the claim about sertraline. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These interventions have also been associated with positive mental health outcomes, such as improved well-being, following treatment in people who use MA.34”
§ Protocol for a systematic review of psychological treatment for methamphetamine use: an analysis of methamphetamine use and mental health symptom outcomes > Introduction > Rationale
What the sources say
- Partly supportedcites [34] matched to “Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders: Randomised controlled trial” (2006) sourceExperimental — accuracy not yet measured
The Results report short-term improvement in depression and improved general functioning after motivational interviewing/CBT. However, these mental-health outcomes are reported for participants with psychotic disorders and substance use generally, not specifically for those who use methamphetamine; the paper discusses amphetamine users separately in relation to substance use. Page numbers are unavailable in our copy. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
In the paper
“The shift to crystal MA use in Australia has seen mental health problems associated with this form of the drug substantially worsen.”
§ Protocol for a systematic review of psychological treatment for methamphetamine use: an analysis of methamphetamine use and mental health symptom outcomes > Introduction > Rationale
What the sources say
- Not matchedcites [13] NSW Health. Crystalline methamphetamine. background paper. 2015. NSW Government (accessed 20 Aug 2015).
We searched by its title and found no matching paper.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“From 2009 to 2014, the annual total number of mental health presentations, overdose and drug and alcohol presentations at NSW public hospital emergency departments related to MA use increased more than sevenfold, from 394 to 296.13”
§ Protocol for a systematic review of psychological treatment for methamphetamine use: an analysis of methamphetamine use and mental health symptom outcomes > Introduction > Rationale
What the sources say
- Not matchedcites [13] NSW Health. Crystalline methamphetamine. background paper. 2015. NSW Government (accessed 20 Aug 2015).
We searched by its title and found no matching paper.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“Psychostimulants are a unique group of substances because they are more likely to induce psychosis than other illicit drugs.14”
§ Protocol for a systematic review of psychological treatment for methamphetamine use: an analysis of methamphetamine use and mental health symptom outcomes > Introduction > Rationale
What the sources say
- Not checked — no full text of the sourcecites [14] matched to “Major physical and psychological harms of methamphetamine use” (2008) source
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
18 more claims
Create a free account to see all 59 claims and every source verdict.
- It may state two separate claims as one. 19
- Probably not a substantial claim. 21
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Knapp WPS, Farrell, M B, Silva de Lima M Psychosocial interventions for cocaine and psychostimulant amphetamines related disorders (Review). Cochrane Database Syst Rev 2007; 18: CD003023. 17636713”
Cited work 10.1002/14651858.cd003023.pub2 · retracted 2015-04-02 · notice 10.1002/14651858.cd003023.pub3 · this paper published 2017-09
Citations
Cites
1 retracted
Psychosocial interventions for cocaine and psychostimulant amphetamines related disorders
Knapp, W. P., Soares, B., Farrell, M., & Silva de Lima, M. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003023.pub2 · Cited by 178
RetractedDiagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2010) · International Journal of Surgery · doi:10.1016/j.ijsu.2010.02.007 · Cited by 12,156
Cohen, J. (1992) · Psychological Bulletin · doi:10.1037//0033-2909.112.1.155 · Cited by 8,771
Vos, T., Barber, R. M., Bell, B., Bertozzi-Villa, A., Biryukov, S., Bolliger, I., Charlson, F., Davis, A., Degenhardt, L., Dicker, D., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60692-4 · Cited by 6,414
Extent of illicit drug use and dependence, and their contribution to the global burden of disease
Degenhardt, L., & Hall, W. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61138-0 · Cited by 1,303 · cited 1×
“The disease burden in Australia attributable to MA is of international relevance as Australia has reputable data for mortality rates, and the rates of illicit drug use are similar to those in other high-income countries.(11) In recent years, a more potent form of MA (crystal) has increased in popularity across the glo…”
ResultEvidence for physiotherapy practice: A survey of the Physiotherapy Evidence Database (PEDro)
Moseley, A. M., Herbert, R. D., Sherrington, C., & Maher, C. G. (2002) · Australian Journal of Physiotherapy · doi:10.1016/s0004-9514(14)60281-6 · Cited by 911 · cited 1×
“If disagreement occurs, final ratings will be made via consensus, following discussion with coauthors.(46) The ‘Cochrane Collaboration’s Risk of Bias’ tool will be used to measure risk of bias(45) with items judged as low, high or unclear risk.”
MethodMajor physical and psychological harms of methamphetamine use
DARKE, S., KAYE, S., McKETIN, R., & DUFLOU, J. (2008) · Drug and Alcohol Review · doi:10.1080/09595230801923702 · Cited by 675 · cited 2×
“Although vulnerability to psychotic symptoms differs among people who use MA, these symptoms are more apparent in people who use MA on a regular basis.(14) In addition, depression, anxiety, suicidal ideation, dysphoria and cognitive deficits have been commonly reported to co-occur in people using MA.”
BackgroundA multi‐site comparison of psychosocial approaches for the treatment of methamphetamine dependence
Rawson, R. A., Marinelli‐Casey, P., Anglin, M. D., Dickow, A., Frazier, Y., Gallagher, C., Galloway, G. P., Herrell, J., Huber, A., McCann, M. J., et al. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00707.x · Cited by 387
Cadet, J. L., Jayanthi, S., & Deng, X. (2003) · The FASEB Journal · doi:10.1096/fj.03-0073rev · Cited by 286
A systematic review of cognitive and behavioural therapies for methamphetamine dependence
LEE, N. K., & RAWSON, R. A. (2008) · Drug and Alcohol Review · doi:10.1080/09595230801919494 · Cited by 255 · cited 1×
“As it is difficult to maintain enduring behaviour changes in people who experience problems with drug use,(29) the longevity of treatment effects relating to long-term abstinence and a range of mental health symptoms or conditions should be further assessed.(38) 39 Cochrane reviews conducted thus far have not focused…”
BackgroundSelf-citationPharmacological approaches to methamphetamine dependence: a focused review
Karila, L., Weinstein, A., Aubin, H., Benyamina, A., Reynaud, M., & Batki, S. L. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03639.x · Cited by 242 · cited 1×
“Pharmacotherapies have been used in conjunction with the aim of improving treatment engagement and retention;(21) however, research on the efficacy of pharmacotherapies to date has produced inconsistent results.(22) There is no evidence to suggest that agonist drug treatments can reduce psychological distress associat…”
MethodBupropion for the treatment of methamphetamine dependence
Elkashef, A. M., Rawson, R. A., Anderson, A. L., Li, S.-H., Holmes, T., Smith, E. V., Chiang, N., Kahn, R., Vocci, F., Ling, W., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301481 · Cited by 234
Baker, A., Lee, N. K., Claire, M., Lewin, T. J., Grant, T., Pohlman, S., Saunders, J. B., Kay‐Lambkin, F., Constable, P., Jenner, L., et al. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.01002.x · Cited by 227
Self-citationContingency Management for the Treatment of Methamphetamine Use Disorders
Roll, J. M., Petry, N. M., Stitzer, M. L., Brecht, M. L., Peirce, J. M., McCann, M. J., Blaine, J., MacDonald, M., DiMaria, J., Lucero, L., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1993 · Cited by 197 · cited 1×
“30 Contingency management (CM) has been shown to be an efficacious psychological treatment for people who use MA(31) and has increased MA abstinence and decreased MA-related risk behaviour.(5) 32 33 Certain psychological interventions, such as cognitive behavioural therapy (CBT) (including the Matrix Model), and appro…”
BackgroundContingency Management for the Treatment of Methamphetamine Use Disorders
Roll, J. M., Petry, N. M., Stitzer, M. L., Brecht, M. L., Peirce, J. M., McCann, M. J., Blaine, J., MacDonald, M., DiMaria, J., Lucero, L., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.11.1993 · Cited by 196
Global patterns of methamphetamine use
Chomchai, C., & Chomchai, S. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000168 · Cited by 170 · cited 6×
“Suvanchot KS, Somrongthong R, Phukhao D. Efficacy of group motivational interviewing plus brief cognitive behavior therapy for relapse in amphetamine users with co-occurring psychological problems at Southern Psychiatric Hospital in Thailand.”
BackgroundResultInfluentialAmphetamine-group substances and HIV
Colfax, G., Santos, G.-M., Chu, P., Vittinghoff, E., Pluddemann, A., Kumar, S., & Hart, C. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60753-2 · Cited by 167
Baker, A., Bucci, S., Lewin, T. J., Kay-Lambkin, F., Constable, P. M., & Carr, V. J. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.188.5.439 · Cited by 159 · cited 3×
“Treatment retention can be difficult for MA users in psychological treatment.21 Pharmacotherapies have been used in conjunction with the aim of improving treatment engagement and retention;21 however, research on the efficacy of pharmacotherapies to date has produced inconsistent results.22 There is no evidence to sug…”
BackgroundSelf-citationCrystalline methamphetamine use and methamphetamine‐related harms in Australia
Degenhardt, L., Sara, G., McKetin, R., Roxburgh, A., Dobbins, T., Farrell, M., Burns, L., & Hall, W. D. (2017) · Drug and Alcohol Review · doi:10.1111/dar.12426 · Cited by 159 · cited 1×
“Increased production and availability of the drug has influenced regular use, consequently increasing drug-related harms.(7) Substance use accounts for an increasing proportion of the global burden of disease.”
BackgroundThe relationship between crystalline methamphetamine use and methamphetamine dependence
McKetin, R., Kelly, E., & McLaren, J. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.04.007 · Cited by 145
Wisdom, J. P., Manuel, J. I., & Drake, R. E. (2011) · Psychiatric Services · doi:10.1176/ps.62.9.pss6209_1007 · Cited by 136
The epidemiology of methamphetamine use and harm in Australia
DEGENHARDT, L., ROXBURGH, A., BLACK, E., BRUNO, R., CAMPBELL, G., KINNER, S., & FETHERSTON, J. (2008) · Drug and Alcohol Review · doi:10.1080/09595230801950572 · Cited by 134 · cited 1×
“In line with the psychological and public health implications of MA use, there has been a considerable amount of research on psychological treatments for treating MA use and withdrawal.(28) Thus, psychological treatment is the primary treatment available for people who use MA, and also appears to have the most solid e…”
BackgroundPsychopathology in methamphetamine-dependent adults 3 years after treatment
GLASNER‐EDWARDS, S., MOONEY, L. J., MARINELLI‐CASEY, P., HILLHOUSE, M., ANG, A., RAWSON, R. A., & THE METHAMPHETAMINE TREATMENT PROJECT CORPORATE AUTHORS (2010) · Drug and Alcohol Review · doi:10.1111/j.1465-3362.2009.00081.x · Cited by 128
Rose, M. E., & Grant, J. E. (2008) · Annals of Clinical Psychiatry · doi:10.1080/10401230802177656 · Cited by 121 · cited 2×
“Overall, it appears that psychological therapies remain the most effective treatment option for MA use, and that pharmacotherapies may be used as an adjunct.(21) As it is difficult to maintain enduring behaviour changes in people who experience problems with drug use,(29) the longevity of treatment effects relating to…”
BackgroundTreatment for amphetamine withdrawal
Shoptaw, S. J., Kao, U., Heinzerling, K., & Ling, W. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003021.pub2 · Cited by 120
Theories of Addiction: Methamphetamine Users' Explanations for Continuing Drug Use and Relapse
Newton, T. F., De La Garza, R., Kalechstein, A. D., Tziortzis, D., & Jacobsen, C. A. (2009) · The American Journal on Addictions · doi:10.1080/10550490902925920 · Cited by 92
Psychosocial interventions for psychostimulant misuse
Minozzi, S., Saulle, R., De Crescenzo, F., & Amato, L. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011866.pub2 · Cited by 90 · cited 1×
“39 Cochrane reviews conducted thus far have not focused on psychological treatment for MA and co-occurring symptoms of mental ill health.(35) 37 40 The present review will focus on studies which have measured MA use and mental health symptomatology or diagnoses at baseline and post-treatment.”
BackgroundClinical course and outcomes of methamphetamine-dependent adults with psychosis
Glasner, S. V., Mooney, L. J., Marinelli‐Casey, P., Hillhouse, M. P., Ang, A., & Rawson, R. A. (2008) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2007.12.004 · Cited by 82 · cited 1×
“Results will assist public health and clinical use of treatment for coexisting MA use and mental health symptoms or conditions.(42) This systematic review represents an important step in summarising the available evidence for psychological treatment for MA use and will allow for identification of areas for future rese…”
BackgroundAnderson, A. L., Li, S.-H., Markova, D., Holmes, T. H., Chiang, N., Kahn, R., Campbell, J., Dickerson, D. L., Galloway, G. P., Haning, W., et al. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.01.036 · Cited by 70 · cited 1×
“24 In a review conducted by Elkashef et al,(25) pharmacotherapies such as bupropion and sertraline did not increase abstinence from MA in groups who received this drug compared with controls.(26) The evidence base for pharmacological approaches for MA use is limited, with conflicting evidence for medication approaches…”
BackgroundTreatment for amphetamine psychosis
Shoptaw, S. J., Kao, U., & Ling, W. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003026.pub3 · Cited by 59
Wisdom, J. P., Manuel, J. I., & Drake, R. E. (2011) · Psychiatric Services · doi:10.1176/appi.ps.62.9.1007 · Cited by 53
A review of treatment options for co-occurring methamphetamine use disorders and depression
Hellem, T. L., Lundberg, K. J., & Renshaw, P. F. (2015) · Journal of Addictions Nursing · doi:10.1097/jan.0000000000000058 · Cited by 51
Tait, R. J., McKetin, R., Kay-Lambkin, F., Carron-Arthur, B., Bennett, A., Bennett, K., Christensen, H., & Griffiths, K. M. (2015) · Journal of Medical Internet Research · doi:10.2196/jmir.3778 · Cited by 43
Psychosocial interventions for psychostimulant misuse
Minozzi, S., Crescenzo, F. D., Saulle, R., & Amato, L. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011866 · Cited by 43
A review of psychological and pharmacological treatment options for methamphetamine dependence
Ciketic, S., Hayatbakhsh, M. R., Doran, C. M., Najman, J. M., & McKetin, R. (2012) · Journal of Substance Use · doi:10.3109/14659891.2011.592900 · Cited by 36 · cited 2×
“Cochrane reviews have assessed treatment for MA withdrawal and found no effective medication approaches.(27) 36 Hellem et al(4) conducted a review on MA and coexisting depressive symptoms, reviewing nine studies incorporating psychological intervention only; psychological”
BackgroundWhich medications are suitable for agonist drug maintenance?
Darke, S., & Farrell, M. (2016) · Addiction · doi:10.1111/add.13158 · Cited by 36
Johnson, B. A., Roache, J. D., Ait-Daoud, N., Wallace, C., Wells, L. T., & Wang, Y. (2005) · Psychopharmacology · doi:10.1007/s00213-004-1998-0 · Cited by 33
Treatment for amphetamine psychosis
Shoptaw, S. J., Kao, U., & Ling, W. W. (2008) · The Cochrane Database of Systematic Reviews (Complete Reviews) · doi:10.1002/14651858.cd003026.pub2 · Cited by 28
KAY‐LAMBKIN, F. J., BAKER, A. L., MCKETIN, R., & LEE, N. (2010) · Drug and Alcohol Review · doi:10.1111/j.1465-3362.2010.00203.x · Cited by 24 · cited 1×
“In summary, it appears that MA use is associated with an array of psychological difficulties that may affect one’s response to treatment.(20) Psychological treatment, incorporating elements such as psychotherapy, psychoeducation and relapse prevention are major treatments for MA use that focus on abstinence and reduci…”
BackgroundSpend today, clean tomorrow: Predicting methamphetamine abstinence in a randomized controlled trial.
Murtaugh, K. L., Krishnamurti, T., Davis, A. L., Reback, C. J., & SHOPTAW, S. J. (2013) · Health Psychology · doi:10.1037/a0032922 · Cited by 24
Reback, C. J., Peck, J. A., Fletcher, J. B., Nuno, M., & Dierst-Davies, R. (2012) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2012.684633 · Cited by 20
Fletcher, J. B., & Reback, C. J. (2013) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2013.03.002 · Cited by 20
Lile, J. A., Stoops, W. W., Glaser, P. E. A., Hays, L. R., & Rush, C. R. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.06.006 · Cited by 16
Male methamphetamine-user inmates in prison treatment: During-treatment outcomes
Joe, G. W., Rowan-Szal, G. A., Greener, J. M., Simpson, D. D., & Vance, J. (2010) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2009.08.002 · Cited by 16
(2012) · PubMed · Cited by 11
METHAMPHETAMINE: WHERE WILL THE STAMPEDE TAKE US?
Sullivan, D. H., & Michael, M. (2015) · PubMed · Cited by 5
[The problem of therapeutic efficacy indices. 2. Description of the indices].
Boissel, J., Buyse, M. E., Cucherat, M., Boutitie, F., Gueyffier, F., Châtellier, G., Li, W., Nony, P., Haugh, M., & Mignot, G. (1999) · PubMed · Cited by 4
Research works printed but not linked: 2
- Shoptaw, 2009, Treatment for amphetamine withdrawal, Cochrane Database Syst Rev, 2
- Boissel, 1999, Methodology outline of the problem of indices of therapeutic efficacy. II the Indices, Therapie, 54, 309
Cited by
Methamphetamine‐associated psychosis: Clinical presentation, biological basis, and treatment options
Chiang, M., Lombardi, D., Du, J., Makrum, U., Sitthichai, R., Harrington, A., Shukair, N., Zhao, M., & Fan, X. (2019) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2710 · Cited by 71
Stuart, A. M., Baker, A. L., Denham, A. M. J., Lee, N. K., Hall, A., Oldmeadow, C., Dunlop, A., Bowman, J., & McCarter, K. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.09.005 · Cited by 49
Self-citationO'Donnell, A. J., Addison, M. T., Spencer, L. P., Zurhold, H., Rosenkranz, M., McGovern, R., Gilvarry, E. A., Martens, M., Verthein, U., & Kaner, E. (2018) · Addiction · doi:10.1111/add.14434 · Cited by 55
“Epidemiological evidence also confirms that psychostimulants are more likely to induce psychosis than other illicit substances [81], with depression, anxiety and suicidal ideation commonly co-occurring among methamphetamine users [82].”
BackgroundMidlife and Older Age Methamphetamine Poisoning Deaths in Hawai‘i
Sidhu, G. K., Fontanilla, T. M., & Becker, T. S. (2024) · Hawai‘i Journal of Health & Social Welfare · doi:10.62547/wwzl3153 · Cited by 2
Psychosocial treatment for methamphetamine use and the associated mental health symptoms
Mann, A., & Wagstaff, C. (2019) · Advances in Dual Diagnosis · doi:10.1108/add-11-2018-0022
Metadata
- Authors
- Stuart, A., Baker, A. L., Bowman, J., McCarter, K., Denham, A. M. J., Lee, N., Colyvas, K., & Dunlop, A.
- Affiliations
- University of Newcastle Australia (AU)
- Curtin University (AU)
- Corresponding author
- Stuart, Alexandra
- ORCID
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2017-09
- Volume
- 7
- Issue
- 9
- Pages
- e015383
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC5595199
- OpenAlex
- W2753891124
- Cited by
- 7
- References
- 55
- Citations by year
- 2026: 1 · 2024: 1 · 2021: 1 · 2019: 3 · 2018: 1
- FWCI
- 0.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HighWire Press Open Archive (acceptedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- methamphetamine use, psychological intervention, psychiatric symptoms, psychosis, depression, anxiety, cognitive impairment, substance use disorders, treatment effectiveness, co-occurring mental illness
- MeSH terms
- Systematic Reviews as Topic, Mental Disorders, Humans, Mental Health, Methamphetamine, Psychotherapy, Research Design
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.